What is "oportuzumab monatox"

n. A monoclonal antibody used as an antineoplastic.

Oportuzumab monatox (proposed INN), trade name "Vicinium" is an antineoplastic. Chemically, oportuzumab it is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). The drug is produced by Viventia Bio International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.

Vicinium has been evaluated in phase I and II clinical trials in patients with non-muscle invasive bladder cancer. In these studies, treatment was associated with clinical benefit.